论文信息 - Very high-risk familial hypercholesterolaemia patients in real life: The remaining gap in achieving the current LDL-C targets despite the use of PCSK9 inhibitors. - 字舞流文

Very high-risk familial hypercholesterolaemia patients in real life: The remaining gap in achieving the current LDL-C targets despite the use of PCSK9 inhibitors.

C. Vlachopoulos | G. Kolovou | L. Rallidis | D. Tousoulis | E. Iliodromitis | E. Liberopoulos | I. Dima | G. Anastasiou | I. Skoumas

[1] M. Gulati,et al. Highlights of Studies in Cardiovascular Disease Prevention Presented at the 2020 American College of Cardiology Annual Scientific Session , 2020, Current Atherosclerosis Reports.

[2] A. Goldberg,et al. Bempedoic acid: a promising novel agent for LDL-C lowering. , 2020, Future cardiology.

[3] C. Vlachopoulos,et al. PCSK9 inhibitors in clinical practice: novel directions and new experiences. , 2019, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

[4] L. Rallidis. The changing landscape of lipid-lowering therapy after the new ESC/EAS guidelines for the management of dyslipidaemias: Launching the era of triple hypolipidaemic therapy in very high risk patients. , 2019, Atherosclerosis.

[5] M. Sabatine,et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.

[6] P. Barter,et al. Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. , 2016, European heart journal. Cardiovascular pharmacotherapy.

[7] G. Kolovou,et al. Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors , 2016, HORMONES.